A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Safety and Efficacy of Mucinex D for Symptomatic Therapy in Patients With Acute Upper Respiratory Tract Who Seek Treatment (Wait and See)

NCT01202279 Phase 4 COMPLETED Results posted

The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo

Details

Lead sponsor	Reckitt Benckiser Inc.
Phase	Phase 4
Status	COMPLETED
Enrolment	1179
Start date	2009-10
Completion	2010-07

Conditions

• Acute Upper Respiratory Track Infection

Interventions

• Guaifenesin
• Placebo

Primary outcomes

• Antibiotic Sparing — Day 7
  Number of patients who received an antibiotic
• Change From Baseline in Total Symptom Score of the Wisconsin Upper Respiratory Symptom Survey - 21 (WURSS-21). — Baseline and 7 Days
  WURSS-21 is made up of 21 questions with a scoring from 0 = no symptom to 7 = severe symptom. With a minimum score of 0 to a maximum score of 147.

Countries

United States